Consent given pursuant to sections 14 and 14A for the importation and supply of the therapeutic goods specified - between 1 December 2014 and 31 December 2015

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods, including medicines, in Australia, aiming to ensure they are of acceptable quality, safety, and efficacy. The Act was introduced to address the need for a robust legal framework governing the approval, import, manufacture, and distribution of therapeutic goods in Australia. Enacted by the Commonwealth Parliament, the Act serves to protect public health by ensuring that therapeutic goods meet necessary standards. In a specific instance, the Act provided the authority for the delegate of the Secretary of the Department of Health to consent to the importation and supply of certain products that do not fully conform to labelling requirements, contingent on compliance with other regulatory standards. This particular consent, issued on 1 December 2014, was granted to Novartis Vaccines and Diagnostics Pty Ltd for their Agrippal inactivated influenza vaccine, due to the physical constraints of the syringe label that prevented full compliance with certain labelling requirements. The consent is strictly conditional and time-bound, underscoring the balance the Act seeks between regulatory compliance and practical considerations in the medical field.

Scope and Application

The Therapeutic Goods Act 1989, as amended and applied in this notice, pertains to the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood and blood components. Specifically, the Act allows for the importation and supply of therapeutic goods that do not fully comply with certain regulatory standards under specific circumstances. In this instance, the Act applies to Novartis Vaccines and Diagnostics Pty Ltd, a company operating within Australia, and their product, the Agrippal inactivated influenza vaccine injection pre-filled syringe. The consent granted by the delegate of the Secretary under the Act permits the company to import and supply this vaccine, which does not meet specific labelling requirements due to the physical constraints of the syringe label. This authorisation is geographically confined to Australia and is in effect from 1 December 2014 until 31 December 2015, subject to compliance with all other relevant regulatory standards. The Act allows for the flexibility to address practical challenges in product presentation while maintaining overall safety and efficacy standards.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, outlines the process for the Therapeutic Goods Administration (TGA) to issue consent for certain therapeutic goods that do not strictly adhere to the labelling requirements of Therapeutic Goods Order No 69. In this instance, the TGA granted Novartis Vaccines and Diagnostics Pty Ltd permission to import and supply the AGRIPPALIN inactivated influenza vaccine, which does not meet the stipulated minimum letter height for the Sponsor name and the full listing of all active ingredients on the syringe label (sections 14 and 14A(1)). This decision was made due to the physical limitations of the syringe label, and the consent is effective from 1 December 2014 until 31 December 2015. Under the Act, the TGA has the authority to impose conditions on such consents to ensure that the therapeutic goods remain safe and of acceptable quality. In this case, the TGA has mandated that, despite the label constraints, the product must still comply with all other relevant aspects of Therapeutic Goods Order 69 and any other applicable standards (section 14A(2)). This ensures that while the specific label requirements are relaxed, the overall safety and quality of the therapeutic goods are not compromised. Novartis Vaccines and Diagnostics Pty Ltd, as the entity benefiting from the consent, has specific obligations under this arrangement. They must ensure that the product complies with all other labelling requirements and standards stipulated by the TGA. This includes adhering to the remaining stipulations of Therapeutic Goods Order 69 and any other applicable regulatory standards to maintain the product's safety and efficacy. Failure to comply with the conditions set by the TGA can lead to serious consequences. Under the Therapeutic Goods Act 1989, any breach of the conditions attached to the consent can result in legal action. Such actions may include fines, product recalls, or even criminal charges depending on the severity of the breach. The maximum penalties for contravening the Act can include substantial fines and, in some cases, imprisonment for individuals found guilty of serious offences. The precise penalties depend on the nature and extent of the breach but underscore the importance of strict adherence to the conditions imposed.